DR. Procyshyn replies

References

1. • Procyshyn RM
   • Zerjav S
   Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine.
   Clin Ther. 1998; 20: 1203-1217
   • Scopus (55)
   • PubMed
   • Abstract
   • Full Text PDF
   • Google Scholar
2. • Addington D
   • Addington J
   Costs of novel antipsychotics in clinical practice.
   in: Poster presented at: 151st Annual Meeting of the American Psychiatric Association, Toronto, CanadaMay 30–June 4, 1998
   • Google Scholar
3. • Chan Y
   • Votolato NA
   • Nasrallah HA
   Pharmacoeconomic comparisons of risperidone and olanzapine during acute treatment of schizophrenia.
   in: Poster presented at: 151st Annual Meeting of the American Psychiatric Association, Toronto, CanadaMay 30–June 4, 1998
   • Google Scholar
4. • Love RC
   • Conley RR
   • Kelly DL
   A dose-outcome analysis of risperidone use in the Maryland State Mental Health System.
   in: Poster presented at: 151st Annual Meeting of the American Psychiatric Association, Toronto, CanadaMay 30–June 4, 1998
   • Google Scholar
5. • Mahmoud RA
   • Engelhart LM
   • Oster G
   • Ollendorf D
   for the Risperidone Outcome Study of Effectiveness (ROSE) Group. Psychiatric resource use under usual care conditions: What is the cost of risperidone's benefits?.
   in: Poster presented at: 151st Annual Meeting of the American Psychiatric Association, Toronto, CanadaMay 30–June 4, 1998
   • Google Scholar
6. • Hamilton SH
   • Revicki DA
   • Edgell ET
   • et al.
   Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: Results from a randomized clinical trial.
   Pharmaco Economics. 1999; 15: 469-480
   • Scopus (104)
   • PubMed
   • Crossref
   • Google Scholar
7. • Tran PV
   • Hamilton SH
   • Kuntz AJ
   • et al.
   Double-blind comparison of olanzapine versus risperi-done in the treatment of schizophrenia and other psychotic disorders.
   J Clin Psychopharmacol. 1997; 17: 407-418
   • Scopus (770)
   • PubMed
   • Crossref
   • Google Scholar
8. • Owens DG
   Olanzapine produced a higher clinical response rate than risperidone in schizophrenia.
   Evid-Based Mental Health. 1998; 1 (Commentary): 55
   • Scopus (2)
   • Crossref
   • Google Scholar
9. • Grainger DL
   • Edgell ET
   • Andersen SW
   • Wang J
   Resource use and quality of life of olanzapine compared with risperidone from an international randomized clinical trial.
   in: Poster presented at: 11th Congress of the European College of Neuropsychopharmacology, Paris, FranceOctober 31–November 4, 1998
   • Google Scholar
10. • Palmer CS
    • Revicki DA
    • Genduso LA
    • et al.
    A cost-effectiveness clinical decision analysis model for schizophrenia.
    Am J Managed Care. 1998; 4: 345-355
    • PubMed
    • Google Scholar
11. • Tollefson GD
    • Beasley CM
    • Tran PV
    • et al.
    Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: Results of an international collaborative trial.
    Am J Psychiatry. 1998; 154: 457-465
    • Google Scholar